#Retatrutide #Peptides #GLP1 #Obesity #DrugDevelopment #PharmaceuticalIndustry #ClinicalTrials #Injectables #CMC #Biologics #global #industry #pharmaceuticals #treatment #antiobesity #news Dr
As a triple agonist targeting GLP-1, GIP, and glucagon receptors, it engages even more pathways than tirzepatide
The medication was generally well tolerated, with a side effect profile consistent with other GLP-1 receptor agonists.
He added that this could come from neurological changes or changes in salivary production (many GLP-1 users report dry mouths)
To view a copy of this licence, visit About this article Cite this article Peri, R.V., Anchan, H., Jonnalagadda, K
People starting tirzepatide who also have migraines should track their headache patterns carefully